Evidence map›Paper›PMID 37318701›Full record

SynthesisJournal of epidemiology and global health2023

The Association of Hypertension with Increased Mortality Rate During the COVID-19 Pandemic: An Update with Meta-analysis.

Ahmad R Al-Qudimat, Ayisha Ameen, Doaa M Sabir, Heba Alkharraz, Mai Elaarag, Aisha Althani, Kalpana Singh, Wassim M Alhimoney, Raed M Al-Zoubi, Omar M Aboumarzouk

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Journal of epidemiology and global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmad R Al-QudimatSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar. aalqudimat@hamad.qa.ORCID 0000-0003-1161-7244
Ayisha AmeenSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.
Doaa M SabirSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0002-2664-9559
Heba AlkharrazSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.
Mai ElaaragSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0001-6192-5654
Aisha AlthaniSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.
Kalpana SinghNursing Research Department, Nursing Corporate, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0002-2273-5062
Wassim M AlhimoneySurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.
Raed M Al-ZoubiSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0002-0548-429X
Omar M AboumarzoukSurgical Research Section, Department of Surgery, Hamad Medical Corporation, Doha, Qatar.ORCID 0000-0002-7961-7614

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimThe impact of multiple risk factors on COVID-19 mortality has been previously reported in multiple systematic reviews and meta-analyses. The aim of this review is to provide a comprehensive update on the association between hypertension (HTN) and mortality in patients with COVID-19.

methodsA systematic review and meta-analysis were performed and followed the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. A search was achieved using PubMed, Scopus, and Cochrane Databases for research publications on hypertension, COVID-19, and mortality published between December 2019 and August 2022.

resultsA total of 23 observational studies involving 611,522 patients from 5 countries (China, Korea, the UK, Australia, and the USA) were included in our study. The confirmed number of COVID-19 with HTN cases in each study ranged from 5 to 9964. The mortality ranged from 0.17% to 31% in different studies. Pooled results show that the mortality rate of COVID-19 among the included studies ranges from a minimum of 0.39 (95% CI 0.13-1.12) to a maximum of 5.74 (95% CI 3.77-8.74). Out of the 611,522 patients, 3119 died which resulted in an overall mortality prevalence of 0.5%. Subgroup analyses indicated that patients with COVID-19 who have hypertension and male patients had slightly less risk of mortality than female patients [the percentage of men > 50%; OR 1.33: 95% CI (1.01, 1.76); the percentage of men ≤ 50%: OR 2.26; and 95% CI (1.15, 4.48)]. Meta-regression analysis results also showed a statistically significant association between hypertension and COVID-19 mortality.

conclusionThis systematic review and meta-analysis suggest that hypertension may not be the only risk factor associated with the increased mortality rate during the COVID-19 pandemic. In addition, a combination of other comorbidities and old age appears to increase the risk of mortality from COVID-19. The impact of hypertension on mortality rate among COVID-19 patients.

Indexed as

COVID-19HypertensionComorbidityFemaleHumansMaleObservational Studies as TopicPandemicsRisk FactorsChronic diseaseCOVID-19HTNMortalityPandemicPrevalence

Identifiers

PMID37318701
PMCPMC10469154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.